ID   NZOV1
AC   CVCL_D811
SY   NZOV-1; NZ-OV1; New Zealand OVarian line 1
DR   Wikidata; Q54931644
RX   PubMed=7718330;
RX   PubMed=19493612;
RX   PubMed=21912889;
CC   Doubling time: 65 hours (PubMed=7718330).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His178Thr; Zygosity=Unspecified (PubMed=21912889).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 9
//
RX   PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H;
RA   Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J.,
RA   McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M.,
RA   van Zijl P.L.;
RT   "Resistance mechanisms determining the in vitro sensitivity to
RT   paclitaxel of tumour cells cultured from patients with ovarian
RT   cancer.";
RL   Eur. J. Cancer 31:230-237(1995).
//
RX   PubMed=19493612; DOI=10.1016/j.canlet.2009.05.010;
RA   Ramachandran A., Marshall E.S., Love D.R., Baguley B.C.,
RA   Shelling A.N.;
RT   "Activin is a potent growth suppressor of epithelial ovarian cancer
RT   cells.";
RL   Cancer Lett. 285:157-165(2009).
//
RX   PubMed=21912889; DOI=10.1007/s10637-011-9744-z;
RA   Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A.,
RA   Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P.,
RA   Ding A., Baguley B.C.;
RT   "Therapeutic reactivation of mutant p53 protein by quinazoline
RT   derivatives.";
RL   Invest. New Drugs 30:2035-2045(2012).
//